125353-44-8

Usage

Uses

Used in Pharmaceutical Industry:
(S)-1,1,1-TRIFLUOROISOPROPYLAMINE HYDROCHLORIDE is used as a reagent in organic chemical reactions for the synthesis of various pharmaceuticals. Its unique properties and versatility enable the creation of a broad spectrum of medicinal compounds, contributing to the development of new and improved treatments.
Used in Agrochemical Industry:
In the agrochemical industry, (S)-1,1,1-TRIFLUOROISOPROPYLAMINE HYDROCHLORIDE is used as a building block in the synthesis of various agrochemicals, including pesticides and herbicides. Its application in this field helps in the development of effective and environmentally friendly solutions for pest and weed control, ensuring sustainable agricultural practices.
Used in Fine Chemical Industry:
(S)-1,1,1-TRIFLUOROISOPROPYLAMINE HYDROCHLORIDE is also employed in the fine chemical industry, where it serves as a key intermediate in the synthesis of specialty chemicals. Its unique properties and reactivity allow for the production of high-quality and high-purity compounds, meeting the stringent requirements of various applications in this industry.

InChI:InChI=1/C3H6F3N.ClH/c1-2(7)3(4,5)6;/h2H,7H2,1H3;1H/t2-;/m0./s1

Upstream product

• 119561-24-9 N-benzylidene(1,1,1-trifluoroisopropyl)amine 
• 34226-10-3 1,1,1-trifluoropropanone oxime 
• 177268-09-6 (S)-2,2,2-Trifluoro-1-p-tolylsulfanylmethyl-ethylamine 
• 1998156-24-3 C₁₀H₁₀F₃NO 
• 811432-45-8 C₁₁H₁₄F₃N 
• 249648-15-5 C₃H₆F₃N*C₄H₆O₆ 

Relevant academic research and scientific papers

Cinchonium Betaines as Efficient Catalysts for Asymmetric Proton Transfer Catalysis: The Development of a Practical Enantioselective Isomerization of Trifluoromethyl Imines

We have developed a new class of cinchonium betaine catalysts bearing both a base moiety and an aromatic moiety as an N-substituent of the quinuclidine motif. These cinchonium betaines were found to promote proton transfer catalysis with 1000-5000 turnovers per 24 h, thereby enabling us to realize highly efficient enantioselective isomerization of trifluoromethyl imines to provide a practical access to optically active trifluoromethylated amines.

1,1,1-Trifluoropropan-2-ammonium triflate enantiomers: stereoselective synthesis and direct use in reaction with epoxides

A three-step synthesis of enantiomerically enriched 1,1,1-trifluoro-2-propanamine based on the use of a chiral sulfinamide auxiliary is described. The reduction of the geometrically pure Z-sulfinimine (NOE, HOE) with NaBH4 or L-Selectride leads to the corresponding (R)- or (S)-configured amine derivatives (X-ray crystallographic analysis) with 92–96% de. The typical models to explain the stereoselection for these reducing agents fail to rationalize the obtained stereoselectivities, and an in situ imine isomerization is proposed to occur. The direct use of the hydrochloric acid salt (with excess Et3N) of this poorly nucleophilic amine for epoxide opening reactions is not possible due to the higher nucleophilicity of chloride. Hence, a novel triflate salt is introduced, synthesized through ready sulfinamide hydrolysis with trimethylsilyl triflate, which can be used directly, without the need of isolating the pure amine beforehand.

DEUTERATED ANALOGS OF AN ORGANIC COMPOUND

Provided are deuterated analogs of a compound and methods of using such deuterated analogs for treating a brain tumor in a patient in need thereof; the treatment comprising administering to the patient a deuterated compound described herein. The deuterated compound may be administered in combination with radiation therapy and/or an additional therapeutic agent.

Discovery of novel HCV inhibitors: Synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B

A novel series of 6-(indol-2-yl)pyridine-3-sulfonamides was prepared and evaluated for their ability to inhibit HCV RNA replication in the HCV replicon cell culture assay. Preliminary optimization of this series furnished compounds with low nanomolar potency against the HCV genotype 1b replicon. Among these, compound 8c has identified as a potent HCV replicon inhibitor (EC50 = 4 nM) with a selectivity index with respect to cellular GAPDH of more than 2500. Further, compound 8c had a good pharmacokinetic profile in rats with an IV half-life of 6 h and oral bioavailability (F) of 62%. Selection of HCV replicon resistance identified an amino acid substitution in HCV NS4B that confers resistance to these compounds. These compounds hold promise as a new chemotype with anti-HCV activity mediated through an underexploited viral target.

Asymmetric synthesis of trifluoromethylated amines via catalytic enantioselective isomerization of imines

A new approach toward the asymmetric synthesis of optically active trifluoromethylated amines was enabled by an unprecedented, highly enantioselective catalytic isomerization of trifluoromethyl imines with a new chiral organic catalyst. Not only aryl but also alkyl trifluoromethylated amines could be obtained in high enantioselectivities.

6-SUBSTITUTED- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS

The present invention provides 6-substituted 2,3,4,5-tetrahydro-lH- benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: R6 D R? N-R" R* where R6 is -(CrC3)alkyl-S-(C0-C3)alkyl-R10, -(C1-C3)alkyl-NR11R12, -(CrC3)alkyl-O- R 13. and other substituents are as defined in the specification.

6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS

The present invention provides 6-substituted 2,3,4,5-tetrahydro-lH- benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is -NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.

PROCESS FOR PRODUCING OPTICALLY ACTIVE 1-ALKYL-SUBSTITUTED 2,2,2-TRIFLUOROETHYLAMINE

The present invention relates to a process for producing an optically active 1-alkyl-substituted 2,2,2-trifluoroethylamine, which is an important intermediate of medicines and agricultural chemicals, and which is represented by the formula [3] [in the for

6-[(SUBSTITUTED)PHENYL]TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS

This invention relates to certain 6-[(substituted)phenyl]triazolopyrimidine compounds or pharmaceutically acceptable salts thereof, and compositions containing said compounds or pharmaceutically acceptable salts thereof, wherein said compounds are anti-cancer agents useful for the treatment of cancer in mammals. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of said compounds or pharmaceutically acceptable salts thereof. The present invention relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal in need thereof by promotion of microtubule polymerization which comprises administering to said mammal an effective amount of said compounds and pharmaceutically acceptable salts thereof.

Process for the preparation of 1,1,1-trifluoro-2-aminoalkanes

An improved process for the preparation of a 1,1,1-trifluoro-2-aminoalkane of formula I wherein R1represents an optionally substituted alkyl group; which comprises hydrogenating the corresponding oxime of formula II wherein R1has the meaning given above and the winding line indicates that the hydroxy group may be in the (E)- or (Z)-position with respect to the trifluoromethyl group, in the presence of Raney nickel and a diluent; the improvement wherein is, that said reaction is carried out in a diluent selected from an alkanol, a cyclic ether and an aromatic hydrocarbon.